Subtopic Deep Dive
GDF15 as Cardiovascular Biomarker
Research Guide
What is GDF15 as Cardiovascular Biomarker?
GDF15 serves as a prognostic cardiovascular biomarker with elevated plasma levels in heart failure, myocardial infarction, and atherosclerosis for risk stratification.
GDF15 levels correlate with NT-proBNP and predict mortality independent of other markers (Daniels et al., 2011, 228 citations; Kempf et al., 2006, 277 citations). Studies show its utility in community-dwelling adults and chronic heart failure patients via immunoradiometric assays (Wiklund et al., 2010, 273 citations). Over 20 papers from 2006-2021 establish its role in multi-marker panels.
Why It Matters
GDF15 refines risk prediction in heart failure with reduced ejection fraction, adding value beyond NT-proBNP (Tromp et al., 2018, 288 citations; Santhanakrishnan et al., 2012, 218 citations). In myocardial infarction, it forecasts death and heart failure when combined with clinical factors (Khan et al., 2009, 219 citations). Its integration into geroscience trials supports personalized cardiovascular management (Justice et al., 2018, 301 citations). Elevated levels in atherosclerosis link to TGF-β pathways (Hanna and Frangogiannis, 2019, 244 citations).
Key Research Challenges
Standardizing GDF15 Assays
Variability in immunoradiometric assays affects comparability across studies (Kempf et al., 2006). Different cutoffs hinder clinical adoption. Calibration against NT-proBNP remains inconsistent (Castiglione et al., 2021).
Distinguishing HFpEF vs HFrEF
GDF15 elevations differ between preserved and reduced ejection fraction heart failure (Santhanakrishnan et al., 2012; Tromp et al., 2018). Prognostic weights vary by subtype. Imaging correlations need validation.
Independent Prognostic Value
GDF15 adds information over NT-proBNP but multi-marker models require optimization (Khan et al., 2009; Daniels et al., 2011). Confounders like age and comorbidities dilute specificity. Longitudinal trials are limited.
Essential Papers
GDF-15 as a Target and Biomarker for Diabetes and Cardiovascular Diseases: A Translational Prospective
Ramu Adela, S. Banerjee · 2015 · Journal of Diabetes Research · 454 citations
Growth differentiation factor-15 (GDF-15) is a stress responsive cytokine. It is highly expressed in cardiomyocytes, adipocytes, macrophages, endothelial cells, and vascular smooth muscle cells in ...
Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint
Jörg Wischhusen, Ignacio Melero, Wolf H. Fridman · 2020 · Frontiers in Immunology · 452 citations
Growth/differentiation factor-15 (GDF-15), also named macrophage inhibitory cytokine-1, is a divergent member of the transforming growth factor β superfamily. While physiological expression is bare...
Biomarkers for the diagnosis and management of heart failure
Vincenzo Castiglione, Alberto Aimo, Giuseppe Vergaro et al. · 2021 · Heart Failure Reviews · 442 citations
A framework for selection of blood-based biomarkers for geroscience-guided clinical trials: report from the TAME Biomarkers Workgroup
Jamie N. Justice, Luigi Ferrucci, Anne B. Newman et al. · 2018 · GeroScience · 301 citations
Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction
Jasper Tromp, B. Daan Westenbrink, Wouter Ouwerkerk et al. · 2018 · Journal of the American College of Cardiology · 288 citations
Circulating Concentrations of Growth-Differentiation Factor 15 in Apparently Healthy Elderly Individuals and Patients with Chronic Heart Failure as Assessed by a New Immunoradiometric Sandwich Assay
Tibor Kempf, Rüdiger Horn-Wichmann, Georg Brabant et al. · 2006 · Clinical Chemistry · 277 citations
Abstract Background: Growth-differentiation factor 15 (GDF15) is a member of the transforming growth factor β (TGF-β) cytokine superfamily. There has been increasing interest in using circulating G...
Macrophage inhibitory cytokine‐1 (MIC‐1/GDF15): a new marker of all‐cause mortality
Fredrik Wiklund, Anna M. Bennet, Patrik K. E. Magnusson et al. · 2010 · Aging Cell · 273 citations
Summary Macrophage inhibitory cytokine‐1 (MIC‐1/GDF15) is a member of the TGF‐b superfamily, previously studied in cancer and inflammation. In addition to regulating body weight, MIC‐1/GDF15 may be...
Reading Guide
Foundational Papers
Start with Kempf et al. (2006, 277 citations) for GDF15 assay validation in heart failure; Daniels et al. (2011, 228 citations) for community mortality prediction; Khan et al. (2009, 219 citations) for MI prognosis.
Recent Advances
Study Castiglione et al. (2021, 442 citations) for HF biomarker overview; Tromp et al. (2018, 288 citations) for ejection fraction differences; Adela and Banerjee (2015, 454 citations) for cardiovascular targeting.
Core Methods
Immunoradiometric assays measure plasma GDF15; Cox regression assesses prognostic value with NT-proBNP; ROC analysis sets thresholds (Kempf et al., 2006; Daniels et al., 2011).
How PapersFlow Helps You Research GDF15 as Cardiovascular Biomarker
Discover & Search
Research Agent uses searchPapers and citationGraph on 'GDF15 heart failure' to map 50+ papers from Kempf et al. (2006), revealing clusters around NT-proBNP correlations. exaSearch uncovers atherosclerosis links; findSimilarPapers extends to Tromp et al. (2018).
Analyze & Verify
Analysis Agent applies readPaperContent to extract GDF15 cutoffs from Daniels et al. (2011), then verifyResponse with CoVe checks mortality predictions against raw data. runPythonAnalysis performs ROC curve stats on plasma levels; GRADE grades evidence as high for prognosis (Castiglione et al., 2021).
Synthesize & Write
Synthesis Agent detects gaps in HFpEF-specific GDF15 data via contradiction flagging across Santhanakrishnan et al. (2012) and Tromp et al. (2018). Writing Agent uses latexEditText for multi-marker tables, latexSyncCitations for 20+ refs, and latexCompile for reports; exportMermaid diagrams biomarker pathways.
Use Cases
"Compare GDF15 survival curves vs NT-proBNP in community cohorts"
Research Agent → searchPapers + citationGraph → Analysis Agent → runPythonAnalysis (Kaplan-Meier with pandas/matplotlib from Daniels et al. 2011 data) → researcher gets plotted hazard ratios and p-values.
"Draft review on GDF15 in myocardial infarction risk panels"
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Khan et al. 2009) + latexCompile → researcher gets LaTeX PDF with formatted sections and citations.
"Find analysis code for GDF15 biomarker thresholds"
Research Agent → paperExtractUrls on Kempf et al. (2006) → paperFindGithubRepo → githubRepoInspect → researcher gets R scripts for assay normalization and thresholds.
Automated Workflows
Deep Research workflow scans 50+ GDF15 papers via searchPapers → citationGraph → structured report with GRADE scores on prognostic utility (e.g., Tromp et al., 2018). DeepScan applies 7-step CoVe to verify GDF15-NT-proBNP interactions from Khan et al. (2009). Theorizer generates hypotheses on GDF15 in HFpEF from Santhanakrishnan et al. (2012) contradictions.
Frequently Asked Questions
What defines GDF15 as a cardiovascular biomarker?
GDF15 is a stress-responsive TGF-β cytokine with elevated plasma levels prognostic for heart failure, infarction, and mortality (Kempf et al., 2006; Daniels et al., 2011).
What methods measure circulating GDF15?
Immunoradiometric sandwich assays quantify GDF15 in plasma, validated in heart failure cohorts (Kempf et al., 2006). Levels >1200 pg/mL predict events independent of NT-proBNP.
What are key papers on GDF15 in heart failure?
Kempf et al. (2006, 277 citations) established assays in chronic HF; Tromp et al. (2018, 288 citations) differentiated HFrEF mechanisms; Santhanakrishnan et al. (2012, 218 citations) compared with ST2 and troponin.
What open problems exist for GDF15 clinically?
Optimal cutoffs for risk stratification, integration into multi-marker panels beyond NT-proBNP, and prospective trials in atherosclerosis remain unresolved (Castiglione et al., 2021; Hanna and Frangogiannis, 2019).
Research GDF15 and Related Biomarkers with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching GDF15 as Cardiovascular Biomarker with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the GDF15 and Related Biomarkers Research Guide